Development and Evaluation of Indole-Based Phospholipase D Inhibitors for Lung Cancer Immunotherapy

This study explored novel immunomodulatory approaches for Cancer treatment, with a specific focus on lung Cancer, the leading cause of cancer-related deaths worldwide. We synthesized indole-based Phospholipase D (PLD) inhibitors with various substituents to improve Anticancer efficacy. Through structure-activity relationship studies, the key compound was identified that significantly inhibiting PLD, suppressing cell growth, viability, and migration in vitro, while inducing Apoptosis of lung Cancer cells. In silico docking studies confirmed its binding to the PLD1 active site, highlighting the role of specific residues in inhibiting PLD1 activity. The inhibitor modulated oncogenic pathways and immune evasion in lung Cancer cells, showing potential for immunotherapy. In vivo experiments in a mouse model showed tumor reduction and immune response alteration. Combining these inhibitors with gemcitabine, an Anticancer drug, synergistically enhanced inhibition of lung Cancer cell Apoptosis and proliferation. This research offers new insights into PLD Inhibitor as potential Cancer therapeutics.